ANGLE plc (AGL) AI Stock Analysis

• Market Cap: £9.76M
• Dividend Yield: N/A
• Average Volume (3M): 2.07M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.43
• Revenue Growth: 29.64%
• EPS Growth: 28.51%
• Country: UK
• Employees: 150
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -0.03
• Shares Outstanding: 322,641,660
• 10 Day Avg. Volume: 2,640,367
• 30 Day Avg. Volume: 2,069,577
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: £4.00
• Price Target Upside: 32.45% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 44 Neutral
• Price Target: 4.00p ▲(32.45% Upside)

ANGLE plc's stock score is primarily impacted by its financial performance and technical analysis. The company is in a growth phase with improving revenues but faces profitability challenges and negative cash flows. Technical indicators show bearish momentum, with the stock trading below key moving averages. Valuation is weak due to negative earnings and lack of dividends. The earnings call provided some positive developments in collaborations and technology, but market challenges and funding needs remain significant concerns.

ANGLE plc Business Overview & Revenue Model

Company Description

ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products. The company develops and commercializes Parsortix cell separation system, which captures and harvests circulating tumor cells in metastatic breast cancer patient blood; and HyCEAD multiplex analysis system for routine and focused multiplex analysis of DNA, RNA or protein biomarkers. The company was founded in 1994 and is based in Guildford, the United Kingdom.

How the Company Makes Money

ANGLE plc generates revenue through the sale of its Parsortix systems and related consumables, including the CTC harvesting kits. The company also earns income from service contracts, collaborations with academic institutions, and pharmaceutical companies engaged in research and clinical trials. Significant partnerships with industry leaders enhance ANGLE's market presence and contribute to its earnings, as they facilitate access to larger client bases and shared research initiatives. Furthermore, ANGLE may also benefit from licensing agreements for its technologies, which can provide additional revenue streams.

ANGLE plc Financial Statement Overview

Summary

ANGLE plc is experiencing revenue growth but faces profitability challenges with negative net profit and cash flows. The balance sheet is stable with low leverage, but declining cash reserves and increasing liabilities are concerns.

Income Statement

ANGLE plc has shown moderate revenue growth over the past years, with a significant increase from $762,000 in 2020 to $2,862,000 in 2024. Gross profit margins have improved, but the net profit margin remains negative due to substantial operating losses. EBIT and EBITDA margins are also negative, indicating challenges in achieving operational profitability. The company is still in a growth phase, focusing on revenue increase while managing high operational costs.

Balance Sheet

The balance sheet of ANGLE plc indicates a stable equity base with a debt-to-equity ratio below industry averages, suggesting conservative leverage usage. The equity ratio remains strong, but declining cash reserves and increasing liabilities pose potential liquidity concerns. Overall, while the company has a solid equity foundation, monitoring cash and liabilities is crucial.

Cash Flow

Operating cash flows remain negative, reflecting ongoing operational challenges. Although there is a slight improvement in free cash flow over the years, it remains negative, indicating the need for external financing to support operations. The cash flow to net income ratios are not favorable, underscoring difficulties in generating sufficient cash from operations.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.86M	2.19M	1.04M	1.01M	762.00K
Gross Profit	1.78M	-408.00K	613.00K	711.00K	597.00K
EBITDA	-13.02M	-19.48M	-22.06M	-15.74M	-12.29M
Net Income	-14.22M	-20.13M	-21.69M	-15.01M	-11.61M
Balance Sheet
Total Assets	25.46M	31.18M	49.87M	47.31M	39.05M
Cash, Cash Equivalents and Short-Term Investments	10.43M	16.22M	31.90M	31.84M	28.62M
Total Debt	4.21M	4.55M	5.00M	2.34M	1.36M
Total Liabilities	7.02M	8.24M	9.80M	6.99M	4.71M
Stockholders Equity	18.44M	22.94M	40.06M	40.33M	34.34M
Cash Flow
Free Cash Flow	-13.89M	-15.12M	-17.94M	-15.80M	-8.35M
Operating Cash Flow	-13.45M	-14.46M	-16.05M	-14.01M	-7.85M
Investing Cash Flow	-48.00K	-203.00K	-1.75M	14.77M	-1.97M
Financing Cash Flow	7.67M	-1.13M	18.10M	18.99M	18.14M

ANGLE plc Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 3.02
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:AGL, the sentiment is Negative. The current price of 3.02 is below the 20-day moving average (MA) of 4.75, below the 50-day MA of 5.42, and below the 200-day MA of 8.74, indicating a bearish trend. The MACD of -0.83 indicates Positive momentum. The RSI at 31.33 is Neutral, neither overbought nor oversold. The STOCH value of 17.72 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:AGL.

ANGLE plc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ABDX	59 Neutral	11.23M	-7.95	―	―	27.60%	1.35%
GDR	51 Neutral	1.59M	-0.07	―	―	125.37%	22.47%
VRCI	49 Neutral	9.84M	-0.33	-111.57%	―	226.45%	53.51%
GENI	49 Neutral	12.34M	-1.75	-393.43%	―	25.05%	65.30%
AGL	44 Neutral	£9.76M	―	-87.18%	―	29.64%	28.51%
PRM	38 Underperform	9.33M	-1.55	52.27%	―	12.19%	18.12%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

ANGLE plc Corporate Events

ANGLE plc Reports Interim Results Amid Market Challenges and Strategic Advances

ANGLE plc reported interim results for the first half of 2025, highlighting successful completion of contracts with major pharma companies like Eisai and AstraZeneca, despite facing revenue pressures due to adverse market conditions. The company has developed a unique DNA dual analysis assay using Illumina NGS, expanding its market reach and enhancing its product offerings. ANGLE continues to face challenges from external conditions such as US policy volatility and tariff uncertainties, which have delayed new projects and collaborations. However, the company remains optimistic about its growth potential with ongoing discussions for new contracts and collaborations, including a significant partnership with Myriad Genetics to adapt a cancer test to a CTC-based sample using ANGLE’s Parsortix system.

The most recent analyst rating on (GB:AGL) stock is a Hold with a £6.50 price target. To see the full list of analyst forecasts on ANGLE plc stock, see the GB:AGL Stock Forecast page.

ANGLE plc Appoints Cavendish as Nominated Adviser and Sole Broker

ANGLE plc has appointed Cavendish Capital Markets Limited as its Nominated Adviser and Sole Broker, effective immediately. This strategic move is expected to enhance ANGLE’s market positioning and potentially impact its operations positively by leveraging Cavendish’s expertise in corporate finance and life sciences, benefiting stakeholders and supporting the company’s growth in the liquid biopsy industry.

The most recent analyst rating on (GB:AGL) stock is a Hold with a £6.50 price target. To see the full list of analyst forecasts on ANGLE plc stock, see the GB:AGL Stock Forecast page.

ANGLE plc to Announce Interim Results Amid Virtual Meeting

ANGLE plc announced it will release its interim results for the first half of 2025 on September 9, 2025. Due to planned tube strikes, the analyst meeting will be held virtually, with a live webcast available for analysts. This announcement is significant for stakeholders as it provides insights into the company’s financial performance and strategic direction, potentially impacting its market positioning in the liquid biopsy industry.

The most recent analyst rating on (GB:AGL) stock is a Hold with a £6.50 price target. To see the full list of analyst forecasts on ANGLE plc stock, see the GB:AGL Stock Forecast page.

ANGLE plc Collaborates with Myriad Genetics to Enhance Cancer Diagnostics

ANGLE plc has announced a collaboration with Myriad Genetics to assess the feasibility of using Parsortix-derived circulating tumour cell (CTC) DNA alongside Myriad’s existing tissue-based diagnostic test. This partnership aims to enhance patient treatment by improving access to genomic data through a simple blood test, potentially impacting the precision medicine field significantly.

The most recent analyst rating on (GB:AGL) stock is a Hold with a £5.50 price target. To see the full list of analyst forecasts on ANGLE plc stock, see the GB:AGL Stock Forecast page.

ANGLE plc’s Parsortix System Advances Cancer Research with New Insights on CTC Clusters

ANGLE plc announced a significant publication in Nature Genetics, highlighting the use of its Parsortix system to study the genetic diversity of circulating tumor cell (CTC) clusters. This research, conducted by Professor Nicola Aceto’s team, underscores the importance of CTC clusters in cancer progression and metastasis, revealing that these clusters are key contributors to genetic diversity and therapy resistance. The findings suggest that targeting CTC clusters could be crucial in halting cancer spread, as they are significantly more metastatic than individual CTCs, which has profound implications for cancer treatment strategies.

The most recent analyst rating on (GB:AGL) stock is a Buy with a £70.00 price target. To see the full list of analyst forecasts on ANGLE plc stock, see the GB:AGL Stock Forecast page.

ANGLE plc Showcases Innovative DNA Dual Analysis at EACR 2025

ANGLE plc presented new data at the EACR 2025 Congress, highlighting its DNA dual analysis approach using the Parsortix system in collaboration with Illumina. The study demonstrated the system’s ability to reveal tumour heterogeneity in lung cancer patients by analyzing both CTC-DNA and ctDNA, offering valuable insights for biopharma partners in identifying drug targets and improving trial outcomes.

The most recent analyst rating on (GB:AGL) stock is a Buy with a £70.00 price target. To see the full list of analyst forecasts on ANGLE plc stock, see the GB:AGL Stock Forecast page.

ANGLE plc Unveils Innovative Assay for Prostate Cancer at EACR 2025

ANGLE plc has presented new data at the European Association for Cancer Research (EACR) Congress, showcasing a novel assay for profiling androgen receptor expression in metastatic prostate cancer. This assay, developed using the Parsortix system, addresses a significant unmet need by enabling sensitive, real-time monitoring of androgen receptor activity, which is crucial for assessing treatment response in prostate cancer trials. The assay’s potential utility for pharmacodynamic assessment could significantly impact the market, which is projected to reach a value of $9.8 billion by 2032, by providing a tool for monitoring drug response and resistance in real-time.

The most recent analyst rating on (GB:AGL) stock is a Buy with a £70.00 price target. To see the full list of analyst forecasts on ANGLE plc stock, see the GB:AGL Stock Forecast page.

ANGLE plc’s Parsortix System Advances Cancer Research with New Studies

ANGLE plc announced the publication of three peer-reviewed studies utilizing its Parsortix system to explore cancer biology and potential therapeutic targets. These studies highlight the system’s role in advancing understanding of tumor cell release during surgery and metastatic progression, offering insights that could guide future cancer treatment strategies. The findings underscore the potential of ANGLE’s technology to contribute to personalized cancer diagnostics and therapeutics, as academic and translational research continue to drive innovation in oncology.

The most recent analyst rating on (GB:AGL) stock is a Buy with a £70.00 price target. To see the full list of analyst forecasts on ANGLE plc stock, see the GB:AGL Stock Forecast page.